晚期非小细胞肺癌基于EBUS-TBNA与组织标本PD-L1结果接受抗PD1治疗的真实世界结局
本研究纳入2016年6月至2019年间接受帕博利珠单抗或纳武利尤单抗治疗的晚期非小细胞肺癌患者145例,其中31.7%基于EBUS-TBNA标本的PD-L1结果治疗,68.3%基于组织标本。后续治疗线中两组结局亦无显著差异。
要点
- EBUS-TBNA标本的PD-L1结果可指导免疫检查点抑制剂治疗。
- 基于EBUS-TBNA与组织标本PD-L1结果治疗的患者生存结局相当。
- 一线帕博利珠单抗治疗中两组OS和PFS无显著差异。
核心结论
- EBUS-TBNA标本的PD-L1结果可指导ICI治疗,其治疗结局与基于组织标本PD-L1结果的患者相当。
研究设计与样本
- 真实世界研究,纳入2016年6月至2019年间接受帕博利珠单抗或纳武利尤单抗治疗的晚期NSCLC患者145例。
- 基于EBUS-TBNA标本PD-L1结果治疗者占31.7%,基于组织标本者占68.3%。
- 记录患者特征、PD-L1表达、治疗线数、疗效(RECIST标准)和生存状态(截至2020年5月14日),评估PFS和OS并估计HR。
主要发现
- 多数患者为转移性疾病,腺癌占64.1%。
- 一线帕博利珠单抗用于61例TPS≥50%患者,其中EBUS-TBNA组16例,组织标本组45例。
- 后续治疗线中,基于EBUS-TBNA vs 组织标本PD-L1结果的中位OS和PFS亦无显著差异(包括校正PD-L1表达后)。
临床怎么用
- 临床可依据EBUS-TBNA标本的PD-L1结果启动免疫检查点抑制剂治疗。
- EBUS-TBNA标本PD-L1检测结果与组织标本结果在指导ICI治疗方面结局可比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed death-ligand 1 (PD-L1) testing is feasible in most specimens acquired using endobronchial ultrasound-guided needle aspiration (EBUS-TBNA). RESEARCH QUESTION: Are the outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) on the basis of PD-L1 expression in EBUS-TBNA samples significantly different from those of patients who are treated on the basis of PD-L1 expression in histological samples? STUDY DESIGN AND METHODS: Patients treated with pembrolizumab or nivolumab between June 2016 and 2019 were included. Patient characteristics, PD-L1 expression, line of treatment, response (Response Evaluation Criteria in Solid Tumors [RECIST] criteria), and vital status (May 14, 2020) were recorded. Progression-free survival (PFS) and overall survival (OS) were assessed, and hazard ratios (HR) estimated. RESULTS: A total of 145 patients were treated with pembrolizumab or nivolumab on the basis of PD-L1 expression in EBUS-TBNA (31.7%) or histological (68.3%) samples. Most had metastatic disease, with a predominance of adenocarcinomas (64.1%). First-line pembrolizumab was administered to 61 patients with tumor proportion score ≥50% in EBUS-TBNA (n = 16) or histology samples (n = 45). Median OS and PFS of patients who received first-line pembrolizumab on the basis of PD-L1 results in EBUS-TBNA vs histology samples were not significantly different (OS 25.8 months vs not reached, respectively; HR, 0.82 [95% CI, 0.34-1.95], P = .651). Similarly, the median OS and PFS of patients who received subsequent lines of treatment on the basis of PD-L1 results in EBUS-TBNA vs histological samples were not significantly different (including after adjustment for PD-L1 expression). INTERPRETATION: These findings suggest that PD-L1 results in EBUS-TBNA samples can guide ICI therapy, with treatment outcomes being comparable to those of patients in whom PD-L1 expression was assessed in histological specimens.
引用
- Tajarernmuang P, Ofiara L, Beaudoin S, et al. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens. Chest. 2021. PMID: 33675792. doi:10.1016/j.chest.2021.02.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。